Rapport Therapeutics Q2 EPS $(0.75) Beats $(0.85) Estimate

Rapport Therapeutics (NASDAQ: RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.85) by 11.45 percent. This is a 55.88 percent increase over losses of $(1.70) per share from the same period last year.